Literature DB >> 20607649

MAPKs are not involved in triptolide-induced cell growth inhibition and apoptosis in prostate cancer cell lines with different p53 status.

Wei Li1, Yong Liu, Xue-Xia Li, Yang Yu, Jing-Jing Wu, Qing Wang, Hong Huo, Li-Ming Wang, Ling Yang.   

Abstract

Triptolide showed excellent antitumor activity against several solid tumors. However, its mechanism has not been fully understood. To further elucidate it, the effects of mitogen activated protein kinases (MAPKs) on the activity of triptolide towards prostate cancer cell lines were investigated in the present study using both LNCaP (p53 positive and androgen-dependent) and PC-3 (p53 deficient and androgen-independent) cells. Our results showed that triptolide exerted potent growth inhibitory and apoptotic effects on both cell lines, and the effects were independent of the expression of p53. Although upregulation of ERK and JNK phosphorylation was observed after the triptolide treatment, the results with inhibitors showed that these MAPKs were not involved in the mechanism of triptolide activity in human prostate cancer cell lines with different p53 status. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20607649     DOI: 10.1055/s-0030-1250076

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  5 in total

1.  Triptolide abrogates growth of colon cancer and induces cell cycle arrest by inhibiting transcriptional activation of E2F.

Authors:  Amanda Oliveira; Georg Beyer; Rohit Chugh; Steven J Skube; Kaustav Majumder; Sulagna Banerjee; Veena Sangwan; Lihua Li; Rajinder Dawra; Subbaya Subramanian; Ashok Saluja; Vikas Dudeja
Journal:  Lab Invest       Date:  2015-04-20       Impact factor: 5.662

2.  Triptolide sensitizes TRAIL-induced apoptosis in prostate cancer cells via p53-mediated DR5 up-regulation.

Authors:  Hu Xiaowen; Sun Yi
Journal:  Mol Biol Rep       Date:  2012-06-17       Impact factor: 2.316

3.  Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression.

Authors:  Weiwei Huang; Tiantian He; Chengsen Chai; Yuan Yang; Yahong Zheng; Pei Zhou; Xiaoxia Qiao; Bin Zhang; Zengzhen Liu; Junru Wang; Changhong Shi; Liping Lei; Kun Gao; Hewei Li; Sue Zhong; Libo Yao; Meng-Er Huang; Ming Lei
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

4.  Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner.

Authors:  Frederick Zhehao Zhang; Derek Hoi-Hang Ho; Roger Hoi-Fung Wong
Journal:  Oncotarget       Date:  2018-04-27

5.  Alteration of Androgen Receptor Protein Stability by Triptolide in LNCaP Cells.

Authors:  Wei Li; Bi-De Liu; Kai Liao; Yong Liu; Zi-Jin Wan; Yu-Fen Dong; Qian-Qian Cao; Qian Zhu; Xiao Gu
Journal:  Medicina (Kaunas)       Date:  2018-05-30       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.